Ascletis Pharma Inc. (1672.HK)
- Previous Close
1.360 - Open
1.330 - Bid 1.320 x --
- Ask 1.350 x --
- Day's Range
1.290 - 1.350 - 52 Week Range
1.210 - 2.870 - Volume
1,498,000 - Avg. Volume
963,457 - Market Cap (intraday)
1.357B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.150 - Earnings Date Mar 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.04
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
www.ascletis.comRecent News: 1672.HK
Performance Overview: 1672.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1672.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1672.HK
Valuation Measures
Market Cap
1.38B
Enterprise Value
-1.10B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.87
Price/Book (mrq)
0.54
Enterprise Value/Revenue
-19.43
Enterprise Value/EBITDA
7.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-255.70%
Return on Assets (ttm)
-7.50%
Return on Equity (ttm)
-5.93%
Revenue (ttm)
56.6M
Net Income Avi to Common (ttm)
-144.72M
Diluted EPS (ttm)
-0.150
Balance Sheet and Cash Flow
Total Cash (mrq)
2.3B
Total Debt/Equity (mrq)
0.36%
Levered Free Cash Flow (ttm)
--
Research Analysis: 1672.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 1672.HK
1672.HK does not have Company Insights